Shanghai Shen Lian Biomedical Corporation

SHSE:688098 Stock Report

Market Cap: CN¥2.3b

Shanghai Shen Lian Biomedical Past Earnings Performance

Past criteria checks 0/6

Shanghai Shen Lian Biomedical's earnings have been declining at an average annual rate of -34.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 1.2% per year.

Key information

-34.4%

Earnings growth rate

-35.3%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate1.2%
Return on equity-1.6%
Net Margin-6.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Shanghai Shen Lian Biomedical Corporation's (SHSE:688098) Shares Climb 44% But Its Business Is Yet to Catch Up

Oct 09
Shanghai Shen Lian Biomedical Corporation's (SHSE:688098) Shares Climb 44% But Its Business Is Yet to Catch Up

Shanghai Shen Lian Biomedical Corporation's (SHSE:688098) Popularity With Investors Is Under Threat From Overpricing

Apr 15
Shanghai Shen Lian Biomedical Corporation's (SHSE:688098) Popularity With Investors Is Under Threat From Overpricing

Revenue & Expenses Breakdown

How Shanghai Shen Lian Biomedical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSE:688098 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24310-2016752
30 Jun 24305-1316351
31 Mar 243081314948
31 Dec 233013213845
30 Sep 232812613143
30 Jun 233134813542
31 Mar 233215313543
31 Dec 223296113739
30 Sep 223739113543
30 Jun 223448912036
31 Mar 2236510612335
31 Dec 2135811012335
30 Sep 213088413028
30 Jun 2133611313332
31 Mar 2132211113130
31 Dec 2033813012332
30 Sep 2033013811330
30 Jun 2027810010829
31 Mar 202579010028
31 Dec 192547810627
31 Dec 182758810521
31 Dec 173029911717
30 Jun 17283891290
31 Mar 17276811250
31 Dec 162687310417
31 Dec 15241761030
31 Dec 1420461930
31 Dec 13193421040

Quality Earnings: 688098 is currently unprofitable.

Growing Profit Margin: 688098 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 688098 is unprofitable, and losses have increased over the past 5 years at a rate of 34.4% per year.

Accelerating Growth: Unable to compare 688098's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 688098 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-2.5%).

Return on Equity

High ROE: 688098 has a negative Return on Equity (-1.6%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 05:16
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Shen Lian Biomedical Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jiarui LuGuosen Securities Co., Ltd.